CFF News
FDA Advisory Panel Rules in Favor of AZLI As we enter the holiday season, I am pleased to share with you some very positive news. Yesterday, a potential CF drug called aztreonam lysine for inhalation was recommended for approval by an advisory panel to the U.S. Food and Drug Administration (FDA). Aztreonam lysine for inhalation (AZLI) is being developed by Gilead Sciences, Inc with support from Cystic Fibrosis Foundation Therapeutics (CFFT). The drug would offer a much-needed antibiotic alternative for cystic fibrosis patients who battle recurrent lung infections and often develop resistance to existing antibiotics. In the fall of 2007, results of the final Phase 3 trials were presented to the FDA in the form of a New Drug Application. At that time, unfortunately, a division of the FDA decided not to issue an approval letter for a number of reasons, which we believed were not sufficient to withhold approval. Working with Gilead we communicated with the FDA urging reconsideration. Fin...